HK1050673A1 - N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them - Google Patents

N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Info

Publication number
HK1050673A1
HK1050673A1 HK03102613A HK03102613A HK1050673A1 HK 1050673 A1 HK1050673 A1 HK 1050673A1 HK 03102613 A HK03102613 A HK 03102613A HK 03102613 A HK03102613 A HK 03102613A HK 1050673 A1 HK1050673 A1 HK 1050673A1
Authority
HK
Hong Kong
Prior art keywords
guanidinoalkylamides
preparation
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
HK03102613A
Other languages
English (en)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Fahad Al-Obeidi
Armin Walser
James Ostrem
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1050673A1 publication Critical patent/HK1050673A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK03102613A 1999-10-30 2003-04-10 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them HK1050673A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (1)

Publication Number Publication Date
HK1050673A1 true HK1050673A1 (en) 2003-07-04

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102613A HK1050673A1 (en) 1999-10-30 2003-04-10 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Country Status (32)

Country Link
US (2) US6472562B1 (ko)
EP (2) EP1095933A1 (ko)
JP (1) JP4658430B2 (ko)
KR (1) KR100981593B1 (ko)
CN (1) CN1249026C (ko)
AR (1) AR026257A1 (ko)
AT (1) ATE264837T1 (ko)
AU (1) AU776797B2 (ko)
BR (1) BR0015186A (ko)
CA (1) CA2389412C (ko)
CZ (1) CZ301855B6 (ko)
DE (1) DE60010113T2 (ko)
DK (1) DK1228039T3 (ko)
EE (1) EE05168B1 (ko)
ES (1) ES2220553T3 (ko)
HK (1) HK1050673A1 (ko)
HR (1) HRP20020372B1 (ko)
HU (1) HUP0203627A3 (ko)
IL (2) IL149209A0 (ko)
ME (1) MEP54708A (ko)
MX (1) MXPA02003805A (ko)
NO (1) NO328016B1 (ko)
NZ (1) NZ518607A (ko)
PL (1) PL203859B1 (ko)
PT (1) PT1228039E (ko)
RS (1) RS50471B (ko)
RU (1) RU2253651C2 (ko)
SI (1) SI1228039T1 (ko)
SK (1) SK286856B6 (ko)
TR (1) TR200201181T2 (ko)
WO (1) WO2001032611A1 (ko)
ZA (1) ZA200203294B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644401B1 (en) * 2003-07-04 2011-03-09 Lonza AG Improved process for supported phase synthesis
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
DK2193196T3 (en) * 2007-09-28 2016-11-07 Portola Pharm Inc Clinical profile of Factor Xa inhibitors, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
CN1118209A (zh) 1993-01-20 1996-03-06 彼得·J·亚历山德罗维克斯 线监视系统
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
NZ263084A (en) * 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
KR100380124B1 (ko) 1994-04-26 2003-08-02 셀렉타이드 코포레이션 인자Xa억제제
RU2154633C2 (ru) * 1994-12-02 2000-08-20 Яманоути Фармасьютикал Ко., Лтд. Производные амидинонафтила и фармацевтическая композиция
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
AU8747598A (en) * 1997-08-27 1999-03-16 Kissei Pharmaceutical Co. Ltd. 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
PT1042287E (pt) 1997-12-24 2005-08-31 Aventis Pharma Gmbh Derivados de indole como inibidores do factor xa
WO1999037643A1 (fr) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
DE60012502T2 (de) * 1999-05-05 2005-07-28 Merck & Co., Inc. Neue cathechole als antimikrobielle mittel

Also Published As

Publication number Publication date
AU1026501A (en) 2001-05-14
MXPA02003805A (es) 2004-10-15
HRP20020372B1 (en) 2011-01-31
EE05168B1 (et) 2009-06-15
KR20020047310A (ko) 2002-06-21
ZA200203294B (en) 2003-01-29
EE200200199A (et) 2003-06-16
CZ20021489A3 (cs) 2002-07-17
AR026257A1 (es) 2003-02-05
MEP54708A (en) 2011-05-10
CA2389412A1 (en) 2001-05-10
EP1228039A1 (en) 2002-08-07
TR200201181T2 (tr) 2002-09-23
SK286856B6 (sk) 2009-06-05
CN1249026C (zh) 2006-04-05
EP1228039B1 (en) 2004-04-21
DE60010113D1 (de) 2004-05-27
PL203859B1 (pl) 2009-11-30
RS50471B (sr) 2010-03-02
NZ518607A (en) 2003-10-31
PL354808A1 (en) 2004-02-23
ES2220553T3 (es) 2004-12-16
HUP0203627A2 (hu) 2003-03-28
CA2389412C (en) 2009-12-01
HUP0203627A3 (en) 2004-12-28
AU776797B2 (en) 2004-09-23
JP4658430B2 (ja) 2011-03-23
YU29702A (sh) 2005-06-10
HRP20020372A2 (en) 2004-08-31
IL149209A0 (en) 2002-11-10
JP2003513066A (ja) 2003-04-08
IL149209A (en) 2007-06-03
DK1228039T3 (da) 2004-08-16
WO2001032611A1 (en) 2001-05-10
US20030162967A1 (en) 2003-08-28
RU2253651C2 (ru) 2005-06-10
CZ301855B6 (cs) 2010-07-14
SI1228039T1 (en) 2004-10-31
ATE264837T1 (de) 2004-05-15
RU2002114041A (ru) 2004-01-20
CN1387508A (zh) 2002-12-25
US6664393B2 (en) 2003-12-16
BR0015186A (pt) 2002-07-23
EP1095933A1 (en) 2001-05-02
PT1228039E (pt) 2004-09-30
NO20022022L (no) 2002-04-29
KR100981593B1 (ko) 2010-09-13
NO20022022D0 (no) 2002-04-29
DE60010113T2 (de) 2005-05-04
US6472562B1 (en) 2002-10-29
SK5782002A3 (en) 2002-10-08
NO328016B1 (no) 2009-11-09

Similar Documents

Publication Publication Date Title
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
PL345539A1 (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
IL127132A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
IL145150A0 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HK1019606A1 (en) Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
ZA200201057B (en) Radiopharmaceutical products and their preparation procedure.
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
IL149209A0 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
HUP0201810A2 (en) Sootepenseone and its derivatives, their preparation and use as medicament
HK1047037A1 (en) Pharmaceutical preparations containing nanosols ofchitosan, and their preparation.
IL146276A0 (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
IL132666A0 (en) Phytoestrogenic pharmaceutical preparations
IL146372A0 (en) Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, processes for their preparation, their use and pharmaceutical preparations comprising them
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
AU5055900A (en) Bacteriocin, preparation and use thereof
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
SI1161434T1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU3971300A (en) 2-aminoethyl-indole derivatives, their preparation and therapeutic use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131021